Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients’ perspective. The aim of this study was to evaluate patient-reported outcomes (PROs) during long-term dupilumab treatment.
Methods
Adults with moderate-to-severe AD who initiated dupilumab through the US manufacturer patient support program and participated in RELIEVE-AD (a prospective patient survey study with a 12-month follow-up) were recontacted 30–36 months post-initiation regardless of current dupilumab use. The online questionnaire consisted of PROs, including the Atopic Dermatitis Control Tool (ADCT), use of concomitant AD therapies, satisfaction with current therapy, global change in itch relative to before dupilumab initiation, non-itch skin symptoms (skin pain/soreness, hot/burning feeling, and sensitivity to touch), flares, Dermatology Life Quality Index, sleep problems, and the AD-specific Work Productivity and Activity Impairment Questionnaire.
Results
Of 698 patients who initiated dupilumab (baseline) and were recontacted, 425 completed the 30–36-month survey. Significant reductions from baseline were reported in concomitant AD therapy use (P < 0.05); 54.4% reported not using other AD medications vs. 12.8% at baseline. At 30–36 months, all results (non-itch skin symptoms, flares, sleep problems, health-related quality of life work/activity impairment, disease control, and treatment satisfaction) were similar to or incrementally better than the 12-month timepoint, with significant improvements vs. baseline (P < 0.001). Global change in itch was reported as “very much better” by 75.3% of respondents. Adequate disease control (score < 7 on ADCT) was reported by 80.7% of respondents, and 86.8% were satisfied with the treatment.
Conclusions
In clinical practice settings, patient-reported benefits of dupilumab were maintained in survey respondents during long-term treatment up to 36 months while the use of concomitant AD therapies reduced.
In the RELIEVE-AD study, adult patients with moderate-to-severe atopic dermatitis reported that effectiveness of dupilumab was maintained during 1 year of follow-up.
Since longer-term data can inform the durability of this response from the perspective of patients in clinical practice settings, patients in the RELIEVE-AD study were recontacted 30–36 months after dupilumab initiation to determine if the treatment effects were maintained from the patient perspective.
What was learned from the study?
In this prospective, longitudinal, real-world study, patients reported maintenance of disease control and treatment satisfaction after 30–36 months of treatment, with a magnitude of improvement from baseline that was better than or comparable to the 12-month evaluation in all outcomes, including symptoms, flares, sleep problems, health-related quality of life, work/activity impairment, disease control, and treatment satisfaction.
Survey respondents reported long-term effectiveness of dupilumab for treatment of moderate-to-severe atopic dermatitis, with benefits observed after 12 months of therapy that were maintained up to 36 months.
Digital Features
This article is published with digital features, including a video abstract, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.23790879.
Anzeige
Introduction
Moderate-to-severe atopic dermatitis (AD) is associated with substantial clinical morbidity, and patients report a negative impact on function, health-related quality of life (HRQoL), and work productivity [1‐3]. While topical and conventional systemic therapies are typically used for first-line treatment, these strategies still result in high rates of uncontrolled disease [4, 5].
Dupilumab, a fully human monoclonal antibody, is approved in the US for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [6]. Since AD is a chronic condition, it is important to determine whether long-term treatment results in sustained benefits, especially from the patient’s perspective. While an open-label extension of a clinical trial showed that the efficacy and safety of dupilumab were maintained for up to 4 years [7], few prospective real-world studies have comprehensively evaluated the long-term patient experience with dupilumab [8], with these studies having either a small sample size or a 1- to 2-year follow-up.
RELIEVE-AD (EaRly REal WorLd PatIent EValuation for DupixEnt in Atopic Dermatitis) was a prospective observational study that used patient-reported outcomes (PROs) to evaluate the effectiveness of dupilumab over a 1-year period in adults with moderate-to-severe AD in clinical practice settings [9]. Patients in RELIEVE-AD achieved rapid and sustained improvements in disease control, HRQoL, and daily activities (including work productivity) through 1 year of treatment and reported reductions in flares, itch, non-itch skin symptoms, and sleep problems; use of other AD therapies was reduced while patient satisfaction with treatment improved. RELIEVE-AD Recontact is a long-term follow-up of the original participants to further evaluate the effectiveness of treatment over an extended timeframe. Patients in RELIEVE-AD were recontacted 30–36 months after initiating dupilumab, and here we report the results of the approximate 3-year follow-up.
Methods
Ethics
The RELIEVE-AD study received institutional review board approval. Patients provided informed consent, and data were anonymized in compliance with the Health Insurance Portability and Accountability Act (HIPAA).
Anzeige
Study Design and Patient Population
Adults with moderate-to-severe AD who were prescribed dupilumab were enrolled in the US dupilumab manufacturer patient support program and consented to participate in questionnaires via an online portal before (baseline) and at prespecified timepoints after dupilumab initiation. Details of the study design and the complete methods used and results obtained over the first 12-month assessment period have previously been published [9]. All participants were recontacted 30–36 months after initiation of dupilumab treatment and were asked to complete the same questionnaire as during previous assessments, regardless of current dupilumab use.
Patient-Reported Outcomes
The questionnaire included validated PRO measures of disease control, HRQoL, and work and activity impairment. Disease control was assessed using the Atopic Dermatitis Control Tool (ADCT; total score range 0–24, with higher scores indicating poorer control and adequate disease control validated as a total score of < 7) [10, 11]. HRQoL was evaluated using the Dermatology Life Quality Index (DLQI), which has a total score range of 0–30, with higher scores indicating a more adverse impact on HRQoL and threshold bands for defining the magnitude of the effect on the patient’s life [12, 13]; a change of 4 points or greater in total score is considered clinically meaningful. The effects of AD on self-reported productivity and activity over the past week were assessed among patients who were employed for pay using the Work Productivity and Activity Impairment Questionnaire specific for AD (WPAI:AD) [14]. Other assessments included questions on whether the patient was taking dupilumab as prescribed; use of concomitant therapies for AD in the past 4 weeks; non-itch skin symptoms over the past week (skin pain or soreness, skin feeling hot or burning, skin sensitivity to touch) using numerical rating scales (NRS) of 0–10 (10 = worst score); effects on sleep that included the sleep item from the ADCT and a stand-alone question on sleep problems over the past week (“Over the past week, did you experience sleep problems because of your atopic dermatitis”); and flares, as previously defined [9], over the past 4 weeks. The Recontact survey also included a stand-alone question on global change in itch compared with before the initiation of dupilumab (“Please choose the response below that best describes the overall change in your itching now compared to just before you started taking dupilumab”), with responses on a 7-point Likert scale ranging from “very much better” to “very much worse.” Another stand-alone question queried patient satisfaction with their current treatment (“How satisfied are you with your current treatment(s) for atopic dermatitis?”), with responses that ranged from “extremely satisfied” to “extremely dissatisfied.”
Statistical Analysis
All survey responses at 30–36 months were evaluated. As in the original analysis [9], outcomes were compared vs. baseline using generalized estimating equations to account for correlated data from the same patients responding at each follow-up. A sensitivity analysis was conducted using pattern-mixture modeling (PMM) for imputation of missing values for selected outcomes [15], adjusted as previously described for demographic and clinical covariates [9]. All structured outcome data that were collected (including data that may overlap with safety-related concepts) are presented in this analysis. Analyses were conducted using SAS Enterprise Guide version 7.1 (SAS Institute, Cary, NC).
Results
Of the 698 patients who initiated dupilumab and completed the baseline assessment, 425 (60.9%) completed the questionnaire at 30–36 months. This population does not include 1 participant who completed the original RELIEVE-AD study but was misdiagnosed and did not have AD. Demographic and clinical characteristics of the Recontact respondents were similar to those who completed the baseline and month-12 surveys (Table 1). Additionally, the baseline demographic and clinical characteristics of patients who completed the survey at 30–36 months were similar to those for the 273 patients who did not (data not shown).
Table 1
Demographic and clinical characteristics
Variable
Patients who initiated dupilumab (n = 698)
Patients who completed the month-12 survey (n = 483)
Patients who completed the long-term survey (30–36 months) (n = 425)
Female
431 (61.7)
296 (61.3)
259 (60.9)
Age, years
46.2 ± 15.5
47.1 ± 15.2
46.8 ± 15.1
Race
White
514 (73.6)
354 (73.3)
307 (72.2)
Black/African American
64 (9.2)
43 (8.9)
42 (9.9)
Asian or Pacific Islander
56 (8.0)
42 (8.7)
40 (9.4)
American Indian/Native American or Alaska Native
7 (1.0)
5 (1.0)
5 (1.2)
Multiple
29 (4.2)
20 (4.1)
17 (4.0)
Other
22 (3.2)
15 (3.1)
10 (2.4)
Declined to answer
6 (0.9)
4 (0.8)
4 (0.9)
Geographic region
Northeast
111 (15.9)
71 (14.7)
68 (16.0)
South
361 (51.7)
242 (50.1)
217 (51.1)
Midwest
105 (15.0)
88 (18.2)
65 (15.3)
West
121 (17.3)
82 (17.0)
75 (17.6)
Age at AD diagnosis, years
27.6 ± 23.1
28.5 ± 23.2
27.9 ± 23.2
Insurance type
Commercial insurance
564 (80.8)
361 (74.7)
321 (75.5)
Medicare
88 (12.6)
75 (15.5)
66 (15.5)
Medicaid
24 (3.4)
16 (3.3)
14 (3.3)
TRICARE
19 (2.7)
15 (3.1)
15 (3.5)
Other type of insurance
39 (5.6)
37 (7.7)
26 (6.1)
No insurance
25 (3.6)
13 (2.7)
10 (2.4)
Do not know
1 (0.1)
5 (1.0)
7 (1.6)
Medical history
Non-seasonal allergiesa
251 (36.0)
168 (34.8)
160 (37.6)
Asthma
225 (32.2)
152 (31.5)
134 (31.5)
Hypertension
188 (26.9)
137 (28.4)
121 (28.5)
Anxiety
173 (24.8)
112 (23.2)
101 (23.8)
Depression
141 (20.2)
92 (19.0)
79 (18.6)
Obesity
102 (14.6)
73 (15.1)
62 (14.6)
Sleep disorders
81 (11.6)
55 (11.4)
51 (12.0)
Anemia
78 (11.2)
56 (11.6)
48 (11.3)
Data are presented as n (%) or mean ± standard deviation unless otherwise indicated
AD atopic dermatitis
aIncludes allergic rhinitis or a runny nose, allergic conjunctivitis or pink eye, food allergies, allergic urticaria or hives, or other allergies
A total of 127 patients (18.2%) permanently discontinued dupilumab. Among those who discontinued, the most common reasons were lack of efficacy and adverse effects, in 33 (26%) and 26 (20%) patients, respectively, followed by cost issues and insurance coverage in 23 (18%) and 19 (15%) patients, respectively. Additionally, 25 patients discontinued dupilumab and subsequently restarted treatment at least once. Across all timepoints, > 97% of patients said they were adhering to the prescribed injection schedule.
At long-term recontact, more than half of the patients (231 of 425; 54.4%) reported not using any medication for AD other than dupilumab in the past 4 weeks vs. 12.8% who were not using any other AD therapies at the time of dupilumab initiation (Fig. 1a). The proportion of patients using other AD therapies at 30–36 months was significantly lower than baseline across all medication categories, including any prescription topical agents, topical steroids, systemic steroids, and systemic immunosuppressants (all P < 0.05; Fig. 1b). At baseline, 82.8% of participants reported using over-the-counter emollients, which decreased to 58.8% by month 30–36.
Fig. 1
Medications for AD used in the previous 4 weeks other than dupilumab. a Number of concomitant medications. b Class of concomitant medications. AD atopic dermatitis, PMM pattern-mixture model. *P < 0.05 and ***P < 0.001 vs. baseline
×
Approximately three-quarters of the Recontact respondents (320 of 425; 75.3%) reported a global change in itch that was “very much better” relative to before dupilumab initiation (Fig. 2a), and 59.1% of respondents had no days of intense episodes of itching over the past week, compared with 3.2% of patients at baseline (P < 0.001; Fig. 2b). Consistent with the 12-month results, 45.9% of patients had no flares over the past 4 weeks, compared with 3.0% of patients at baseline (Table 2).
Fig. 2
Itch symptoms. a Global change in itch at the 30–36-month recontact assessment relative to itch before initiation of dupilumab treatment. b Patients with no days of intense episodes of itching over the past week based on item 2 of the Atopic Dermatitis Disease Control Tool. PMM pattern-mixture model. ***P < 0.001 vs. baseline
Table 2
Patient-reported outcomes of flares, skin symptoms, sleep, quality of life, and work and activity impairment
Outcome
Baseline (n = 698)
Month 12 (n = 483)a
Month 30–36 (n = 425)a
Percent of patients reporting no flares in the past 4 weeks, (PMM range)b
3.0
43.5 (41.4–43.5)
45.9 (42.6–45.9)
Non-itch skin symptoms NRS score,
(PMM range)b,c
Skin pain
5.9 ± 2.5
1.7 ± 2.2 (1.3–3.1)
1.5 ± 2.0 (1.0–3.1)
Hot/burning skin
5.2 ± 2.9
1.5 ± 2.1 (1.1–2.8)
1.2 ± 1.9 (0.8–2.7)
Skin sensitivity
5.5 ± 2.9
1.5 ± 2.2 (1.1–2.9)
1.2 ± 1.9 (0.8–2.8)
Percent of patients reporting sleep problems in the past week, (PMM range)b
77.5
14.1 (14.1–16.2)
13.4 (12.7–15.1)
Percent of patients reporting no trouble falling/staying asleep in the past week, (PMM range)b,d
15.3
77.6 (56.2–82.2)
81.6 (52.9–82.2)
DLQIe
Total score, (PMM range)b
14.4 ± 7.3
3.5 ± 4.9 (2.7–7.5)
3.2 ± 4.8 (2.2–8.1)
Percent of patients achieving a clinically meaningful change, (PMM range)b
–
82.6 (65.0–85.4)
84.9 (61.7–87.7)
Percent of patients reporting no effect of AD on the patient’s life, (PMM range)b
1.1
46.2 (32.1–58.4)
52.5 (32.1–66.8)
WPAI:AD, (PMM range)a,f
Percent total work impairment
40.3 ± 28.1
9.6 ± 17.9 (7.0–24.0)
8.6 ± 17.1 (5.2–22.9)
Percent activity impairment
45.6 ± 28.4
10.8 ± 19.5 (8.3–24.0)
9.4 ± 17.7 (6.5–23.5)
Data are presented as % of patients or mean ± standard deviation unless otherwise indicated
AD atopic dermatitis, ADCT Atopic Dermatitis Control Tool, DLQI Dermatology Life Quality Index, NRS numerical rating scale, PMM pattern-mixture model, WPAI:AD Work Productivity and Activity Impairment Questionnaire specific for Atopic Dermatitis
aP < 0.001 vs. baseline
bPMM range is imputed based on n = 698 for follow-up
cScore range is 0–10, with 10 = worst score
dBased on item 4 of the ADCT
eTotal score ranges from 0 to 30, with higher scores indicating a greater impact; a change of ≥ 4 points in total score is clinically meaningful, and scores of 0–1 are interpreted as no effect of AD on a patient’s life
fEvaluated among patients who were employed full or part time or were self-employed and worked more than 0 h during the previous 7 days: n = 494, 322, and 278 for baseline, month-12, and long-term timepoints, respectively
×
Results for all other PROs were similar to or incrementally better than at the 12-month timepoint and showed significant improvements vs. baseline (all P < 0.001; Table 2 and Figs. 2, 3). The NRS scores for the non-itch skin symptoms of skin pain, skin feeling hot/burning, and skin sensitivity (Table 2) represent reductions from baseline of 74.6%, 76.9%, and 78.2%, respectively. Patients also continued to report less sleep disturbance in the previous week, as indicated by the low proportion (13.4% vs. 77.5% at baseline) of patients with sleep problems and the high proportion (81.6% vs. 15.3% at baseline) who had no trouble falling/staying asleep (Table 2).
Fig. 3
Disease control and satisfaction with treatment. a Disease control assessed using the patient-reported ADCT. b Satisfaction with current treatment based on a stand-alone question. ADCT Atopic Dermatitis Control Tool, PMM pattern-mixture model. ***P < 0.001 vs. baseline
×
Anzeige
On the DLQI, the mean total score ± standard deviation of 3.2 ± 4.8 at the long-term assessment was significantly lower than at baseline (14.4 ± 7.3), and most patients (84.9%) had a change from baseline of ≥ 4 points, which is clinically meaningful (Table 2). More than half the patients (52.5%) also reported DLQI scores of 0–1, which indicated no effect of AD on their life, vs. 1.1% at baseline. These long-term effects on HRQoL were similar to those at 12 months (Table 2). Scores for all subscales of the DLQI (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment) showed trends that were similar to the total score (i.e., changes from baseline were statistically significant [all P < 0.001] and scores that were at least as good as at 12 months [data not shown]). Additionally, significant reductions from baseline reported by patients for both work and activity impairment on the WPAI:AD at 12 months were further maintained at the long-term assessment (Table 2). Among the 278 patients who were employed for pay at long-term recontact and had worked in the previous week, impairment of work was 8.6% and impairment of daily activities was 9.4%, and these values were lower than the 40.3% and 45.6% impairment, respectively, reported at baseline (both P < 0.001).
Consistent with the improvement in clinical symptoms and other PROs, the mean total ADCT score (Fig. 3a) was indicative of adequately controlled AD and reflected an incremental benefit of 13.6% from month 12 and a 75.9% improvement from baseline; all individual items of the ADCT showed improvements from baseline, ranging from 64% for severity of eczema-related symptoms to 86% for trouble falling or staying asleep (all P < 0.001; data not shown). Adequately controlled AD was reported by 80.7% of patients, similar to month 12 (77.4%) and higher than baseline (5.9%; Fig. 3a). Patients also reported greater satisfaction with treatment than at baseline (Fig. 3b); 75.5% of patients were “extremely” or “very” satisfied with treatment, vs. 2.8% at baseline.
The PMM ranges representing the sensitivity analysis were generally consistent with the primary analysis, albeit the wide ranges for some outcomes were reflective of the higher number of missing values at this extended timepoint (Figs. 1, 2b, 3, and Table 2).
Discussion
This real-world analysis of patients who were recontacted 30–36 months after initiating treatment with dupilumab extends the 1-year results of the RELIEVE-AD study. Among patients with moderate-to-severe AD who completed the survey, patient-reported benefits achieved at 12 months were maintained at 30–36 months. Most of these patients considered their AD to be adequately controlled while also reporting significant reductions in use of concomitant medications for AD. Sensitivity analyses that accounted for missing values confirmed the robustness of the results. These results also expand on previous reports of the real-world effectiveness of dupilumab by providing a substantially longer follow-up and using a broader range of outcomes relevant to the daily life of patients than studies that mainly focused on clinical measures of disease activity and HRQoL [16‐21].
Anzeige
While itch is the predominant symptom, AD is associated with a multidimensional burden [2, 3] and, similarly, the benefits of long-term dupilumab treatment were multidimensional. These benefits not only encompassed substantial improvements in itch and other patient-reported symptoms (flares, non-itch skin symptoms), but also in functional outcomes, HRQoL, and simplification of treatment. Improvements in the clinical symptoms over the first year of dupilumab treatment were sustained or improved through long-term follow-up. The sustained improvements in itch, in particular, were supported by the responses to the global change in itch question, which, although only collected at the Recontact survey, indicate the magnitude of the patient’s perception of the improvement relative to before dupilumab initiation.
Continued improvement at 30–36 months was also observed for measures of AD-related sleep disturbance and HRQoL, where 85% of patients achieved a clinically meaningful improvement in DLQI score and more than half (53%) reported that AD had no effect on their lives. It has been reported that, in patients with AD, the longitudinal course of itch, sleep disturbances, and HRQoL are heterogeneous, with these symptoms manifesting fluctuating patterns over time [22‐24]. However, the sustained benefits in these outcomes that were reported by patients over the entire assessment period suggest that the improvements relative to baseline likely result from treatment effects rather than fluctuation in symptom presentation. The low rates of work and activity impairment, which were substantially reduced from baseline, not only demonstrate improved daily function from the patient’s perspective but are also relevant from the societal perspective, as improved work productivity may reduce the economic burden of AD [25, 26].
The effectiveness of dupilumab treatment for these patient-reported clinical and functional outcomes is consistent with the high proportion of patients who also reported adequate disease control and satisfaction with treatment. It is important to note that disease control was maintained even with decreasing use of concomitant therapies for AD. While uncontrolled AD has previously been shown to be associated with a higher patient-reported disease burden, disease control in those studies was based on clinical measures or a physician’s report [4, 27, 28], whereas the current study relied on the patient-reported ADCT score.
The main limitation of this analysis is that it reflects a self-selected population, as those who maintain long-term efficacy and safety may be more likely to participate in such a survey. However, the baseline characteristics of patients who responded at 30–36 months were similar to those of the non-respondents. Furthermore, discontinuations appeared to be consistent with other real-world studies with follow-up periods of 1–2 years [29‐31]. A similar limitation is that participants were recruited through the dupilumab patient support program, which may influence patient perceptions of treatment benefit. To mitigate the risk of bias, patients were assured that their survey responses were confidential, reported in aggregate for research purposes, and would not affect their care. Recall bias represents another potential limitation. However, other than the global change in itch and use of concomitant therapies, the other outcomes had a maximum recall period of 1 week.
Anzeige
Conclusions
This prospective observational study demonstrated continued improvements in clinical symptoms, function and activity, and HRQoL through 30–36 months of follow-up in adults with moderate-to-severe AD who were treated with dupilumab in clinical practice. Improved outcomes reported by patients included flares, itch and non-itch skin symptoms, and sleep. These improvements were reflected by patients reporting adequate disease control and a reduced impact of AD on their lives. All improvements were observed in the context of decreased use of other AD medications and increasing patient-reported satisfaction with their AD treatment.
These findings on the long-term, real-world outcomes of dupilumab add to the evidence from clinical trials and other real-world studies of patients receiving dupilumab for moderate-to-severe AD.
Acknowledgements
Funding
This study, the Rapid Service Fee was sponsored by Sanofi and Regeneron Pharmaceuticals Inc.
Medical Writing, Editorial, and Other Assistance
The authors would like to thank the patients who participated in this study. Medical writing support was provided by E. Jay Bienen, PhD, and funded by Sanofi and Regeneron Pharmaceuticals Inc.
Author Contributions
All authors contributed substantially to this manuscript. Alexa B. Kimball, Dimittri Delevry, Min Yang, Zhixiao Wang, Jessie Wang, Jingdong Chao, and Bruce Strober contributed to the study concept or design, and Dimittri Delevry, Min Yang, Zhixiao Wang, Jessie Wang, and Jingdong Chao acquired the data. All authors contributed to the data analysis or interpretation. All authors read and approved the final version.
Disclosures
Alexa B. Kimball is a consultant and investigator for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; an investigator for AnaptysBio and Incyte; a consultant for Bayer, Boehringer Ingelheim, Concert Pharmaceuticals, Lilly, Sanofi, Sonoma Biotherapeutics, and Ventyx Biosciences; has received fellowship funding from AbbVie and Janssen; and serves on the board of directors for Almirall. Dimittri Delevry, Zhixiao Wang, Brad Shumel, and Jingdong Chao are employees of and stockholders in Regeneron Pharmaceuticals Inc. Min Yang, Bruno Martins, Eric Wu, and Jessie Wang are employees of Analysis Group, Inc., which received research funds from Sanofi/Regeneron Pharmaceuticals Inc. during the conduct of the study. Chien-Chia Chuang, Gaëlle Bégo-Le-Bagousse, and Debra Sierka are employees of and stockholders in Sanofi. Bruce Strober is a consultant for AbbVie, Almirall, Alumis, Amgen, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aristea Therapeutics, Asana BioSciences, Boehringer Ingelheim, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, EPI Health, Evelo Biosciences, Immunic Therapeutics, Janssen, LEO Pharma, Maruho, Meiji Seika, Mindera Health, Novartis, Ono Pharmaceutical, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Sun Pharma, UCB Pharma, UNION therapeutics, Ventyx Biosiences, and vTv Therapeutics; holds stock options in Connect Biopharma and Mindera Health; is a speaker for AbbVie, Eli Lilly, Incyte, Janssen, Regeneron Pharmaceuticals Inc., and Sanofi; is a scientific co-director (received consulting fees) of CorEvitas (formerly Corrona) Psoriasis Registry; is an investigator for AbbVie, Cara Therapeutics, CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis; and is editor-in-chief (honorarium) of the Journal of Psoriasis and Psoriatic Arthritis.
Compliance with Ethics Guidelines
The study received approval from the New England independent review board (Needham, MA, USA). All patients provided informed consent, and patient data were anonymized in compliance with the Health Insurance Portability and Accountability Act (HIPAA).
Data Availability
The datasets generated in the current study are in the publication, and additional data are available from the corresponding author on reasonable request.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
verfasst von
Alexa B. Kimball Dimittri Delevry Min Yang Chien-Chia Chuang Zhixiao Wang Gaëlle Bégo-Le-Bagousse Bruno Martins Eric Wu Brad Shumel Jessie Wang Debra Sierka Jingdong Chao Bruce Strober
Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.
Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.
Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.
Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.
In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln. Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.
